Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8IV48
UPID:
ERI1_HUMAN
Alternative names:
3'-5' exonuclease ERI1; Eri-1 homolog; Histone mRNA 3'-end-specific exoribonuclease; Histone mRNA 3'-exonuclease 1; Protein 3'hExo
Alternative UPACC:
Q8IV48; A8K4U7; Q9NSX3
Background:
3'-5' exoribonuclease 1, also known as ERI1, plays a pivotal role in RNA metabolism, specifically in the degradation of histone mRNAs post-replication. It exhibits a unique preference for RNA substrates with a 2' and 3'-hydroxyl group at the last nucleotide, essential for efficient RNA decay. ERI1's ability to degrade siRNAs suggests a regulatory role in RNA interference, a critical pathway in gene expression. Furthermore, its binding affinity for specific RNA sequences and stem-loop structures underscores its importance in RNA processing.
Therapeutic significance:
Understanding the role of 3'-5' exoribonuclease 1 could open doors to potential therapeutic strategies.